Our partners

BD&L has executed a broad range of early to clinical-stage partnerships with companies, universities, and institutions. In addition, the team is involved in securing government contracts for influenza vaccines. Transactions include:

• Gen-Probe, January 2009: Extension and expansion of a blood screening collaboration
• US Department of Health and Human Services (HHS), January 2009: Award for activities to achieve FDA licensure of the US flu cell culture facility in Holly Springs, NC
• AlphaVax, Inc., December 2008: Novel Cytomegalovivus (CMV) vaccine
• Crucell N.V., July 2008: Access to additional markets for Quinvexem®
• Dynavax, July 2008: Novel Universal Influenza vaccine
• GSK, December 2007: Supply of components for GSK’s pediatric vaccine programs
• MedImmune, August 2007: Reverse Genetics technology for influenza applications
• Intercell, July 2007: Broad access to more than 10 projects in preclinical and early-stage development
• US Department of Health and Human Services (HHS), January 2007: Government contract to stockpile vaccine supplies in the event of a pandemic influenza outbreak
• Intercell, June 2006: Phase III-stage Japanese Encephalitis Vitus vaccine in multiple markets worldwide
• US Department of Health and Human Services (HHS), May 2006: Cell culture-derived influenza vaccine development contract
• Panacea Biotec Limited, September 2004: Joint Venture (JV) for formulating, marketing and distributing vaccines in India